NEW YORK, NY—For patients with pure native aortic regurgitation (AR) who are undergoing TAVI, use of devices tailored to treat the AR seems to provide superior outcomes compared with off-label use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback